Skye Bioscience: CFO Resigns; CEO Named Acting Principal Financial Officer

What Happened
Skye Bioscience, Inc. announced in an 8‑K that John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer, effective September 8, 2026. The company notified Lohman & Associates, Inc. that it is terminating the Master Services Agreement dated March 31, 2026, effective September 8, 2026. The Board appointed Punit Dhillon — Skye’s President and Chief Executive Officer — as the company’s principal financial and accounting officer effective September 8, 2026; Mr. Dhillon will continue as CEO and director and his compensation terms remain unchanged. The filing also states that Mr. Sharp’s departure was not the result of any disagreement with the company or its independent auditors.

Key Details

• CFO resignation: John P. Sharp stepped down effective September 8, 2026; departure not due to disagreements with auditors or company.
• Interim financial officer: Punit Dhillon (President & CEO) appointed principal financial and accounting officer effective September 8, 2026; no change in his pay.
• Service agreement terminated: Master Services Agreement with Lohman & Associates, Inc. (dated March 31, 2026) terminated effective September 8, 2026.
• Nasdaq compliance & transaction update: Nasdaq confirmed Skye regained compliance with the $1.00 minimum bid rule after 10 consecutive business days (Aug 24–Sep 4, 2026). Skye also reiterated plans to file a proxy statement in connection with its proposed acquisition of Redx Pharma Limited.

Why It Matters
A CFO resignation and the CEO taking on the principal financial officer role are material governance events investors should note — they can affect financial reporting bandwidth and leadership continuity until a new CFO is named. Termination of the Lohman services agreement may change how the company receives finance/accounting support. Regaining Nasdaq compliance removes an immediate listing risk. Separately, the proposed Redx acquisition is a significant strategic transaction that will require a proxy and contains numerous identified risks; investors should watch for the forthcoming proxy, any updated filings, and disclosures about integration, financing, and timing.